Fischer S, Rath T, Neurath M F
Medizinische Klinik 1, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Deutschland.
Internist (Berl). 2018 Jul;59(7):681-693. doi: 10.1007/s00108-018-0442-1.
Inflammatory bowel diseases (IBD) are complex diseases. Epidemiological studies suggest rising incidences in industrialized countries. The article is based on a literature search in PubMed and is oriented on the current guidelines published by the European Crohn's and Colitis Organisation. IBD are characterized by chronic diarrhoea, abdominal pain and peranal haemorrhage. Extraintestinal manifestations commonly affect joints, skin, eyes and bile tracts. Early diagnosis and therapeutic intervention determine individual patient outcome. Medical treatment currently includes aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors and biologicals. IBDs require anti-inflammatory and if necessary immunosuppressive therapy. Due to extraintestinal complications and the possible need for surgical intervention, an interdisciplinary approach is important.
炎症性肠病(IBD)是复杂的疾病。流行病学研究表明,工业化国家的发病率呈上升趋势。本文基于在PubMed上的文献检索,并以欧洲克罗恩病和结肠炎组织发布的现行指南为导向。IBD的特征为慢性腹泻、腹痛和肛周出血。肠外表现通常累及关节、皮肤、眼睛和胆道。早期诊断和治疗干预决定个体患者的预后。目前的药物治疗包括氨基水杨酸类、皮质类固醇、硫唑嘌呤、钙调神经磷酸酶抑制剂和生物制剂。IBD需要抗炎治疗,必要时进行免疫抑制治疗。由于存在肠外并发症以及可能需要手术干预,多学科方法很重要。